Do Disease-Modifying Anti-rheumatic Drugs and Exercise Therapy Have a Combined Effect on Disease Activity in Patients with RA? A Scoping Review

被引:0
|
作者
Sobejana, M. [1 ]
van der Esch, M. [1 ,2 ]
van den Hoek, J. [1 ]
Kitas, G. [3 ,4 ]
van der Leeden, M. [1 ,5 ]
Nurmohamed, M. T. [1 ,6 ]
Metsios, G. S. [7 ]
机构
[1] Amsterdam Rehabil Res Ctr, Ctr Rehabil & Rheumatol, POB 58271, NL-1040 HG Amsterdam, Netherlands
[2] Amsterdam Univ Appl Sci, Fac Hlth, Ctr Expertise Urban Vital, Amsterdam, Netherlands
[3] Russells Hall Hosp, Dudley Grp NHS Fdn Trust, Clin Res Unit, Dudley, England
[4] Univ Birmingham, Sch Sports & Exercise Sci, Birmingham, England
[5] Vrije Univ, Amsterdam Univ, Dept Rehabil Med, Med Ctr,Amsterdam Movement Sci Res Inst, Amsterdam, Netherlands
[6] Univ Amsterdam, Med Ctr, Dept Rheumatol, Amsterdam, Netherlands
[7] Univ Thessaly, Dept Nutr & Dietet, Trikala, Thessaly, Greece
关键词
Rheumatoid arthritis; Anti-rheumatic drug treatment; DMARDs; Exercise; DAS; RHEUMATOID-ARTHRITIS; CARDIORESPIRATORY FITNESS; STRENGTH; CACHEXIA; PROGRAM; MUSCLE; RISK;
D O I
10.1007/s11926-023-01098-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of Review In addition to disease-modifying anti-rheumatic drug (DMARD) treatment, exercise is increasingly promoted in patients with rheumatoid arthritis (RA). Although both are known to reduce disease activity, few studies have investigated the combined effects of these interventions on disease activity. The aim of this scoping review was to provide an overview of the reported evidence on whether a combined effect-i.e., a greater reduction in disease activity outcome measures-can be detected in studies where an exercise intervention was performed in addition to the DMARD treatment in patients with RA. This scoping review followed the PRISMA guidelines. A literature search was performed for exercise intervention studies in patients with RA treated with DMARDs. Studies without a non-exercise control group were excluded. Included studies reported on (components of) DAS28 and DMARD use and were assessed for methodological quality using version 1 of the Cochrane risk-of-bias tool for randomized trials. For each study, comparisons between groups (i.e., exercise + medication vs. medication only) were reported on disease activity outcome measures. Study data related to the exercise intervention, medication use, and other relevant factors were extracted to assess what may have influenced disease activity outcomes in the included studies. Recent Findings A total of 11 studies were included of which 10 between-group studies on DAS28 components were made. The remaining one study focused on within-group comparisons only. Median duration of the exercise intervention studies was 5 months, and the median number of participants was 55. Six out of the 10 between-group studies reported no significant differences between groups in DAS28 components between exercise + medication vs. medication only. Four studies showed significant reductions in disease activity outcomes for the exercise + medication group compared with the medication-only group. Most studies were not adequately designed methodologically in order to investigate for comparisons of DAS28 components and had a high risk of multi-domain bias. Whether the simultaneous application of exercise therapy and DMARD medication in patients with RA has a combined effect on disease outcome remains unknown, due to weak methodological quality of existing studies. Future studies should focus on the combined effects by having disease activity as the primary outcome.
引用
收藏
页码:69 / 81
页数:13
相关论文
共 50 条
  • [41] USE OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN A COHORT OF PATIENTS WITH IGG4-RELATED DISEASE
    Fernandez-Codina, A.
    Pinal-Fernandez, I.
    Orozco-Galvez, O.
    Solans-Laque, R.
    Bujan-Rivas, S.
    Fonollosa-Pla, V.
    Vilardell-Tarres, M.
    Martinez-Valle, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 398 - 398
  • [42] Combined treatment with leflunomide and methotrexate for patients with disease-modifying anti-rheumatic drugs naive active rheumatoid arthritis
    Lee, S.
    Park, Y.
    Kang, Y.
    Nam, E.
    Kim, S.
    Lee, J.
    Yoo, W.
    Lee, S.
    Park, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 342 - 342
  • [43] EFFECT OF GENDER ON DISEASE-MODIFYING ANTI-RHEUMATIC DRUG (DMARD) PRESCRIPTION IN RHEUMATOID ARTHRITIS (RA)
    Morrison, E.
    Hampson, R.
    Tierney, A.
    MacKenzie, L.
    Capell, H. A.
    RHEUMATOLOGY, 2004, 43 : 46 - 46
  • [44] Rational disease-modifying anti-rheumatic drug (DMARD) therapy: Is it possible?
    Furst, DE
    BRITISH JOURNAL OF RHEUMATOLOGY, 1996, 35 (08): : 707 - 708
  • [45] Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs
    Au, WY
    Ma, ESK
    Choy, C
    Chung, LP
    Fung, TK
    Liang, R
    Kwong, YL
    AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (01) : 5 - 11
  • [46] A PICTORIAL LEAFLET FOR COMBINED DISEASE-MODIFYING ANTI-RHEUMATIC DRUG THERAPY IN EARLY RHEUMATOID ARTHRITIS
    Balendra, Salini
    Ahmed, Azeem
    Price, Elizabeth
    Collins, David
    Williamson, Lyn
    RHEUMATOLOGY, 2014, 53 : 121 - 121
  • [47] Recurrent amenorrhoea associated with disease-modifying anti-rheumatic drugs: a case report
    Ladhari, C.
    Torre, A.
    Pers, Y. -M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (05) : 1035 - +
  • [48] Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients
    Convertino, Irma
    Cazzato, Massimiliano
    Tillati, Silvia
    Giometto, Sabrina
    Gini, Rosa
    Valdiserra, Giulia
    Cappello, Emiliano
    Ferraro, Sara
    Bonaso, Marco
    Bartolini, Claudia C.
    Paoletti, Olga
    Lorenzoni, Valentina
    Filippi, Matteo
    Turchetti, Giuseppe
    Cristofano, Michele
    Blandizzi, Corrado
    Mosca, Marta
    Lucenteforte, Ersilia
    Tuccori, Marco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 488 - 489
  • [49] INFECTIOUS COMPLICATIONS AS A REASON FOR THE CANCELLATION OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Aronova, E.
    Gridneva, G.
    Kudryavtceva, A.
    Dydykina, I.
    Lukina, G.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S250 - S250
  • [50] USE OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS IN QUEBEC, CANADA
    Roussy, J. P.
    Bessette, L.
    Bernatsky, S.
    Rahme, E.
    Legare, J.
    Lachaine, J.
    VALUE IN HEALTH, 2011, 14 (07) : A316 - A316